KNSA Insider Trading Activity and SEC Form 4 Filings
KNSA insider trading summary
Over the past 12 months, insiders at Kiniksa Pharmaceuticals International, plc (KNSA) reported 82 sales worth $116.0M by 7 insiders and no open-market purchases on SEC Form 4. Net insider selling was $116.0M.
Latest KNSA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 4, 2026 | Sanj K Patel | Chairman & CEO | Sell | $2.8M (29,845 @ $95.48) |
| Nov 4, 2026 | Sanj K Patel | Chairman & CEO | Sell | $2.6M (26,918 @ $96.05) |
| Nov 4, 2026 | Sanj K Patel | Chairman & CEO | Sell | $135K (1,460 @ $92.35) |
| Nov 4, 2026 | Sanj K Patel | Chairman & CEO | Sell | $1.1M (11,335 @ $93.54) |
| Nov 4, 2026 | Sanj K Patel | Chairman & CEO | Sell | $7.7M (81,742 @ $94.20) |
| Nov 3, 2026 | Sanj K Patel | Chairman & CEO | Sell | $432K (4,584 @ $94.25) |
| Nov 3, 2026 | Sanj K Patel | Chairman & CEO | Sell | $6.4M (68,664 @ $92.70) |
| Nov 3, 2026 | Sanj K Patel | Chairman & CEO | Sell | $110K (1,214 @ $90.77) |
| Nov 3, 2026 | Sanj K Patel | Chairman & CEO | Sell | $13.6M (145,708 @ $93.53) |
| Nov 2, 2026 | Mark Ragosa | Chief Financial Officer | Sell | $1.3M (14,027 @ $91.40) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.